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Abstract
Idiopathic chronic neutropenia (ICN) describes a heterogeneous group of hematologic diseases characterized by
low circulating neutrophil levels often associated with recurrent fevers, chronic mucosal inflammation, and severe
systemic infections. The severity and risk of complications, including serious infections, are inversely proportional to
the absolute neutrophil count (ANC), with the greatest problems occurring in patients with an ANC of less than 0.5
×1 0
9/L. This case report describes a 64-year-old female with longstanding rheumatoid arthritis who subsequently
developed ICN with frequent episodes of sepsis requiring hospitalization and prolonged courses of antibiotics over
a 4-year period. She was treated with granulocyte colony stimulating factors (G-CSF) but had a delayed, highly
variable, and volatile response. She was enrolled in a clinical trial evaluating the oral investigational agent
ezatiostat. Ezatiostat, a glutathione S-transferase P1-1 inhibitor, activates Jun kinase, promoting the growth and
maturation of hematopoietic progenitor stem cells. She responded by the end of the first month of treatment with
stabilization of her ANC (despite tapering and then stopping G-CSF), clearing of fever, and healing of areas of
infection. This ANC response to ezatiostat treatment has now been sustained for over 8 months and continues.
These results suggest potential roles for ezatiostat in the treatment of patients with ICN who are not responsive to
G-CSF, as an oral therapy alternative, or as an adjunct to G-CSF, and further studies are warranted.
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Background
Idiopathic chronic neutropenia (ICN) is an uncommon
heterogeneous hematologic disorder characterized by
persistent severe neutropenia leading to life-threatening
infections [1]. Granulocyte colony stimulating factor (G-
CSF) has been an effective therapy for increasing blood
neutrophil levels in these patients, and the correspond-
ing reduced frequency of fevers, inflammation, and
infections has resulted in an improved quality of life.
Medical management of neutropenia is mainly sympto-
matic and consists of antibiotic treatment of febrile
patients suspected of having bacterial infections. Other
therapies of uncertain efficacy include glucocorticoids,
lithium, androgenic steroids, immunoglobulins, and
plasmapheresis [2-8].
Although alternative treatment approaches such as
administration of granulocyte/macrophage-GCF and
corticosteroids have been occasionally reported, G-CSF
is the generally accepted treatment for the amelioration
of neutropenia in ICN. However, there is no consensus
for the dose and duration of G-CSF therapy. This is
mainly due to the fact that all data for idiopathic
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comprising cases with diverse underlying pathogenetic
mechanisms. The decision for the necessity of G-CSF
administration, dose, and short- or long-term duration
of treatment is individualized on the basis of infection
risk and general clinical judgment rather than the ANC
per se. Another important issue is prevention of osteo-
porosis in ICN patients. It has been shown that treat-
ment with biophosphates significantly improves
osteopenia/osteoporosis in these patients. The beneficial
effect of the treatment is associated with a reduction in
serum levels of IL-1b and TNF-a and, occasionally, with
amelioration of neutropenia, substantiating the impor-
tant role of these inflammatory cytokines in the patho-
physiology of ICN [9].
Most patients respond to daily subcutaneous adminis-
tration of G-CSF; however, a subgroup of patients do
not respond. ICN patients undergoing chronic G-CSF
therapy often experience bone and muscle pain as well
as thrombocytopenia and splenomegaly complicating
their therapy.
Ezatiostat is an investigational agent in development
for the treatment of a variety of neoplastic and non-neo-
plastic hematologic disorders, including myelodysplastic
syndrome (MDS), and has demonstrated significant
improvement in the induction of growth and differentia-
tion of hematologic precursor stem cells as well as an
increase in apoptosis of malignant cells. Ezatiostat is an
inhibitor of the enzyme glutathione S-transferase P1-1
(GSTP1-1), a negative regulator of Jun kinase (JNK).
Treatment of human cells with ezatiostat leads to the
activation of JNK, which promotes the growth and dif-
ferentiation of hematopoietic stem cell precursors. Eza-
tiostat treatment has shown significant improvement in
neutrophil levels in several clinical trials in MDS
[10-15]. We report here a patient with longstanding
ICN who achieved a complete and sustained hematolo-
gic response following treatment with ezatiostat.
Case presentation
A 64-year-old female with a history of rheumatoid
arthritis (RA) since 1985, treated in the past with a vari-
ety of agents, including methotrexate, steroids, gold,
Imuran, Enbrel, and Humira. The dose and duration of
treatments are not available. The patient had borderline
leukopenia and neutropenia documented as early as
2001 but developed a more progressive severe neutrope-
nia in 2007. There was no periodicity or cyclical neutro-
penia. She did not have splenomegaly. Her bone
marrow revealed 20-30% cellularity with mild erythroid
hyperplasia and mild myeloid and megakaryocyte hypo-
plasia. There was non-specific lymphocytosis and no
dysplasia. The maturation was orderly, with 27% ery-
throblasts, 1% myeloblasts, and 30% neutrophils and
precursors. She experienced numerous hospitalizations
for sepsis as a consequence of her neutropenia, with
white blood cell counts in the 2000-3000 range and neu-
trophils less than 5%, hemoglobin of 12.1 gm/dL, and
platelet count of 186,000. Rheumatoid factor (RF) was
67 iu, and cyclic citrullinated peptide IgG antibody
(CCP-IgG) was > 250 u. Anti-nuclear antibodies varied
between negative and 1:160 with a homogeneous pat-
tern. In the 6 months prior to starting G-CSF, her clini-
cal status deteriorated, with multiple admissions to the
hospital, fevers as high as 103.8°F, non-healing perineal
ulcers, and decubitus ulcers requiring treatment with
broad-spectrum intravenous antibiotics. Fevers fre-
quently recurred within 4 days following cessation of
parenteral antibiotics, necessitating their resumption.
She also suffered from dysphagia and underwent gastro-
intestinal evaluation with endoscopies, which showed
only non-specific gastritis.
She was found to have a small clone of T-gamma lym-
phocytes (0.8%) in the bone marrow and peripheral
blood (confirmed by PCR), but did not respond to ster-
oid pulses or cyclosporine. She had transient moderate
renal dysfunction, with a creatinine rising to 3.2 before
returning to normal in 4 weeks after cessation of cyclos-
porine. She was then treated with PEG-filgrastim with-
out response and thereafter with G-CSF at doses as high
as 600 mcg/day for 3 months. Following an initial
response to G-CSF with some wound healing, her neu-
tropenia became intermittently more severe. Two
methylprednisolone dose packs were given during an
arthritis flare one month before the study observation
period. She was experiencing grade 4 neutropenia and
agreed to participate in a phase 2 clinical trial of ezatio-
stat (Telintra, TLK199). Her median screening absolute
neutrophil count (ANC) priort oe n t e r i n gt h e2 - m o n t h
observation period was 0.18 × 10
9/L. The patient
received RA treatment while on study, including fish oil,
hydroxychloriquine at the start of cycle 7, and acetami-
nophen or ibuprofen as needed. She received ezatiostat
at 2000 mg orally, daily for 21 days of a 28-day cycle,
and has continued on ezatiostat therapy. Initially, G-CSF
was continued along with the ezatiostat, but tapered and
stopped by the end of cycle 2. Her ANC continued to
respond after cessation of G-CSF for 8 months and
continues.
Her post-ezatiostat treatment median ANC was 3.1 ×
10
9/L. Figure 1 shows the striking improvement in ANC
counts beginning with ezatiostat treatment initiation
and continuing to respond when G-CSF use was
stopped. Figure 1 shows the inadequate ANC response
to G-CSF during the baseline run-in period (ANC of .1-
.2 × 10
9/L), as well as post-ezatiostat improvement in
ANC counts. Her complete blood counts have remained
normal, with an ANC ranging between 1.60-3.75 × 10
9/
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months of ezatiostat treatment, the T-gamma clone
could no longer be identified by flow cytometry but per-
sisted by PCR evaluation. RF had normalized (7 iu) but
CCP-IgG remained > 250 u. She has shown remarkable
clinical improvement with complete clearing of her
arthritic symptoms and with an increase of her Kar-
nofsky performance status from 50% to 90%, and she
remains in complete remission from ICN. Accompany-
ing the improvement in her ANC, she experienced a
persistent infection-free period and has not required
hospitalizations or antibiotic therapy since her ANC
improvement. This patient has tolerated ezatiostat well,
reporting only grade 1 nausea, abnormal urine and stool
odor, and a metallic taste.
Discussion
Ezatiostat, a glutathione analog, has shown significant
effects on growth and differentiation of human bone
marrow progenitor stem cells in several preclinical mod-
els of myelopoiesis [16,17]. Ezatiostat causes myeloproli-
feration and differentiation of normal hematopoietic
stem cell precursors and apoptosis of malignant cells by
disrupting the GSTP1-1/JNK signaling pathway. The
mechanism of action of ezatiostat is through the inhibi-
tion of GSTP1-1 that results in activation of the JNK
pathway. GSTP1-1 has been shown in biochemical
assays to be a negative regulator of JNK [18] as well as
ERK2. Treatment with ezatiostat in NIH3T3 cells has
shown that ezatiostat disrupts the binding of GSTP1-1
to both JNK and ERK2, leading to their activation. Eza-
tiostat has been evaluated in multiple phase 1 and phase
2 clinical trials in MDS, a syndrome characterized by
ineffective hematopoiesis presenting with anemia and, in
some cases, neutropenia and thrombocytopenia. Ezatio-
stat is the first inhibitor of GSTP1-1 that was shown to
cause a clinically significanta n ds u s t a i n e dr e d u c t i o ni n
red-blood-cell transfusions, transfusion-independence,
and multilineage hematologic improvement responses in
MDS. Recently, results of a phase 2 multicenter study
that evaluated ezatiostat in MDS were reported where
ezatiostat was shown to be an active agent with multili-
neage responses that was well-tolerated in the MDS
population [5-7].
We report this unique case of a patient with long-
standing ICN who had an inadequate response to G-
CSF therapy and required multiple hospitalizations for
recurrent infections resulting from her chronic grade 4
Figure 1 Absolute neutrophil count showed an inadequate response to G-CSF and ANC response to ezatiostat treatment.
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tiostat and has shown an impressive hematologic
response that is durable and continues. This suggests a
potential role for this agent, given its novel mechanism
of action, in the treatment of patients with ICN. The
oral formulation is potentially of interest for these
patients with ICN, since flexibility in dosing and patient
convenience in the treatment of a chronic disease such
as ICN would be preferable to chronic subcutaneous
injections of G-CSF.
Conclusions
Ezatiostat, a GSTP1-1 inhibitor, activates JNK, promot-
ing the growth and maturation of hematopoietic pro-
genitor stem cells. This case highlights an important
observation that ezatiostat produced a striking and sus-
tained hematologic response in ANC in an ICN patient
who had an inadequate response to G-CSF. Following
8 cycles of treatment with ezatiostat, she has continued
to show remarkable improvement, with an ongoing
complete remission from ICN without further G-CSF
or need for antibiotics. Her symptomatic improvement
has been dramatic. The role of ezatiostat in the sup-
pression of her arthritic symptoms is unclear but may
indicate an observation for further evaluation in
patients with RA. Additionally, since ezatiostat is an
oral agent, it offers ICN patients who require chronic
therapy the convenience and flexibility of oral dosing.
The results of this case report suggest a potential role
for ezatiostat in the treatment of patients with ICN
who are not adequately responsive to G-CSF or as an
adjunct to G-CSF.
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